Literature DB >> 30594394

A developmentally regulated spliced variant of PTBP1 is upregulated in type 1 diabetic hearts.

KarryAnne Belanger1, Curtis A Nutter2, Jin Li3, Peng Yu3, Muge N Kuyumcu-Martinez4.   

Abstract

Alternative splicing (AS) is dysregulated in Type 1 diabetic (T1D) hearts but mechanisms responsible are unclear. Here, we provide evidence that the RNA binding protein (RBP) PTBP1 is modulated in adult T1D hearts contributing to AS changes. We show that a spliced variant of PTBP1 that is highly expressed in normal newborn mouse hearts is aberrantly expressed in adult T1D mouse hearts. Comparing known PTBP1-target datasets to our T1D mouse transcriptome datasets, we discovered a group of genes with PTBP1 binding sites in their pre-mRNAs that are differentially spliced in T1D mouse hearts. We demonstrated that inducible expression of diabetes-induced PTBP1 spliced variant has less repressive splicing function. Notably, PTBP1 regulates AS of some of its targets antagonistically to RBFOX2. In sum, our results indicate that diabetic conditions disrupt developmental regulation of PTBP1 leading to differential AS of PTBP1 target genes. Identification of PTBP1 and PTBP1-regulated RNA networks can provide RNA-based therapies for the treatment of diabetes cardiac complications.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alternative splicing; Diabetic heart; PTBP1; RNA binding proteins

Mesh:

Substances:

Year:  2018        PMID: 30594394      PMCID: PMC6330148          DOI: 10.1016/j.bbrc.2018.12.150

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  43 in total

Review 1.  Turning on a fuel switch of cancer: hnRNP proteins regulate alternative splicing of pyruvate kinase mRNA.

Authors:  Mo Chen; Jian Zhang; James L Manley
Journal:  Cancer Res       Date:  2010-10-26       Impact factor: 12.701

Review 2.  Emerging roles of RNA-binding proteins in diabetes and their therapeutic potential in diabetic complications.

Authors:  Curtis A Nutter; Muge N Kuyumcu-Martinez
Journal:  Wiley Interdiscip Rev RNA       Date:  2017-12-27       Impact factor: 9.957

3.  Structure of PTB bound to RNA: specific binding and implications for splicing regulation.

Authors:  Florian C Oberstrass; Sigrid D Auweter; Michèle Erat; Yann Hargous; Anke Henning; Philipp Wenter; Luc Reymond; Batoul Amir-Ahmady; Stefan Pitsch; Douglas L Black; Frédéric H-T Allain
Journal:  Science       Date:  2005-09-23       Impact factor: 47.728

4.  Dynamic balance between activation and repression regulates pre-mRNA alternative splicing during heart development.

Authors:  Andrea N Ladd; Myrna G Stenberg; Maurice S Swanson; Thomas A Cooper
Journal:  Dev Dyn       Date:  2005-07       Impact factor: 3.780

5.  An intronic splicing silencer causes skipping of the IIIb exon of fibroblast growth factor receptor 2 through involvement of polypyrimidine tract binding protein.

Authors:  R P Carstens; E J Wagner; M A Garcia-Blanco
Journal:  Mol Cell Biol       Date:  2000-10       Impact factor: 4.272

6.  Differential alternative splicing activity of isoforms of polypyrimidine tract binding protein (PTB).

Authors:  M C Wollerton; C Gooding; F Robinson; E C Brown; R J Jackson; C W Smith
Journal:  RNA       Date:  2001-06       Impact factor: 4.942

7.  Dynamic antagonism between ETR-3 and PTB regulates cell type-specific alternative splicing.

Authors:  Nicolas Charlet-B; Penny Logan; Gopal Singh; Thomas A Cooper
Journal:  Mol Cell       Date:  2002-03       Impact factor: 17.970

Review 8.  Defining the roles and interactions of PTB.

Authors:  Panagiota Kafasla; Ian Mickleburgh; Miriam Llorian; Miguel Coelho; Clare Gooding; Dmitry Cherny; Amar Joshi; Olga Kotik-Kogan; Stephen Curry; Ian C Eperon; Richard J Jackson; Christopher W J Smith
Journal:  Biochem Soc Trans       Date:  2012-08       Impact factor: 5.407

9.  Multiple determinants of splicing repression activity in the polypyrimidine tract binding proteins, PTBP1 and PTBP2.

Authors:  Niroshika M Keppetipola; Kyu-Hyeon Yeom; Adrian L Hernandez; Tessa Bui; Shalini Sharma; Douglas L Black
Journal:  RNA       Date:  2016-06-10       Impact factor: 4.942

10.  The splicing regulator PTBP1 controls the activity of the transcription factor Pbx1 during neuronal differentiation.

Authors:  Anthony J Linares; Chia-Ho Lin; Andrey Damianov; Katrina L Adams; Bennett G Novitch; Douglas L Black
Journal:  Elife       Date:  2015-12-24       Impact factor: 8.140

View more
  5 in total

1.  Identification of candidate biomarkers and pathways associated with type 1 diabetes mellitus using bioinformatics analysis.

Authors:  Madhu Pujar; Basavaraj Vastrad; Satish Kavatagimath; Chanabasayya Vastrad; Shivakumar Kotturshetti
Journal:  Sci Rep       Date:  2022-06-01       Impact factor: 4.996

Review 2.  Advances in the study of RNA-binding proteins in diabetic complications.

Authors:  Xinyue Chen; Jiaqiang Wu; Zhangwang Li; Jiashu Han; Panpan Xia; Yunfeng Shen; Jianyong Ma; Xiao Liu; Jing Zhang; Peng Yu
Journal:  Mol Metab       Date:  2022-05-18       Impact factor: 8.568

3.  MicroRNA‑133b alleviates doxorubicin‑induced cardiomyocyte apoptosis and cardiac fibrosis by targeting PTBP1 and TAGLN2.

Authors:  Zhen Li; Zekang Ye; Jiazheng Ma; Qian Gu; Jianzhen Teng; Xiaoxuan Gong
Journal:  Int J Mol Med       Date:  2021-05-13       Impact factor: 4.101

4.  Zika Virus Infection Alters Gene Expression and Poly-Adenylation Patterns in Placental Cells.

Authors:  Stephanea L Sotcheff; John Yun-Chung Chen; Nathan Elrod; Jun Cao; Elizabeth Jaworski; Mugé N Kuyumcu-Martinez; Pei-Yong Shi; Andrew L Routh
Journal:  Pathogens       Date:  2022-08-18

5.  Perfluorooctanoic acid (PFOA) or perfluorooctane sulfonate (PFOS) and DNA methylation in newborn dried blood spots in the Upstate KIDS cohort.

Authors:  Sonia L Robinson; Xuehuo Zeng; Weihua Guan; Rajeshwari Sundaram; Pauline Mendola; Diane L Putnick; Robert A Waterland; Chathura J Gunasekara; Kurunthachalam Kannan; Chongjing Gao; Erin M Bell; Edwina H Yeung
Journal:  Environ Res       Date:  2020-12-30       Impact factor: 6.498

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.